文献速递肝病消化道肿瘤与早癌

肝细胞癌患者恶病质普遍存在且与不良预后相关

Cachexia is Prevalent in Patients With Hepatocellular Carcinoma and Associated With Worse Prognosis.
PubMed 文献 · Clin Gastroenterol Hepatol · 2021-09-20

这项回顾性队列研究纳入两个美国医疗系统2008至2018年诊断的604例肝细胞癌患者,发现诊断时23.7%存在恶病质、33.3%存在前恶病质。恶病质患者接受抗肿瘤治疗的可能性更低,生存期更短,且在校正多因素后仍独立与更差生存相关。

要点

  • 肝细胞癌诊断时近1/4患者存在恶病质,1/3存在前恶病质。
  • 恶病质患者接受肝细胞癌治疗的可能性更低(OR 0.38)。
  • 恶病质独立预测更差生存(HR 1.43),应早期识别。

核心结论

  • 肝细胞癌患者诊断时恶病质普遍存在,且是不良预后的早期独立预测因素。

研究设计与样本

  • 回顾性队列研究,纳入2008至2018年美国两个医疗系统诊断的604例肝细胞癌患者。
  • 记录诊断前6个月及诊断时体重,恶病质定义为体重丢失>5%(BMI<20 kg/m2时>2%),前恶病质定义为体重丢失2%至5%。
  • 采用多因素logistic回归分析恶病质相关因素,多因素Cox比例风险模型分析总生存相关因素。

主要发现

  • 604例患者中,201例(33.3%)存在前恶病质,143例(23.7%)存在恶病质。
  • BCLC 0/A、B、C、D期患者恶病质比例分别为19.0%、23.5%、34.7%、34.0%。
  • 恶病质患者接受肝细胞癌治疗的可能性更低(OR 0.38,95%CI 0.21-0.71)。
  • 恶病质、前恶病质、体重稳定患者生存期分别为11.3、20.4、23.5个月(P<.001)。
  • 校正年龄、性别、种族、民族、Child-Pugh分级、甲胎蛋白、BCLC分期及肝细胞癌治疗后,恶病质仍独立与更差生存相关(HR 1.43,95%CI 1.11-1.84)。

临床怎么用

  • 对肝细胞癌患者应在诊断时常规评估体重变化,识别恶病质和前恶病质。
  • 恶病质提示预后不良且可能影响治疗接受度,应纳入预后评估和临床决策。

局限性

  • 回顾性队列研究设计,可能存在选择偏倚和残余混杂。
  • 仅纳入两个美国医疗系统患者,外推性需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Cancer cachexia is a wasting syndrome associated with functional impairment and reduced survival that impacts up to 50% of patients with gastrointestinal cancers. However, data are limited on the prevalence and clinical significance of cachexia in patients with hepatocellular carcinoma (HCC). METHODS: We performed a retrospective cohort study of patients diagnosed with HCC at 2 United States health systems between 2008 and 2018. Patient weights were recorded 6 months prior to and at time of HCC diagnosis. Cachexia was defined as >5% weight loss (or >2% weight loss if body mass index <20 kg/m2), and precachexia was defined as 2% to 5% weight loss. We used multivariable logistic regression models to identify correlates of cachexia and multivariable Cox proportional hazard models to identify factors associated with overall survival. RESULTS: Of 604 patients with HCC, 201 (33.3%) had precachexia and 143 (23.7%) had cachexia at diagnosis, including 19.0%, 23.5%, 34.7%, and 34.0% of patients with Barcelona Clinic Liver Cancer stages 0/A, B, C, and D, respectively. Patients with cachexia were less likely to receive HCC treatment (odds ratio, 0.38; 95% confidence interval, 0.21-0.71) and had worse survival than those with precachexia or stable weight (11.3 vs 20.4 vs 23.5 months, respectively; P < .001). Cachexia remained independently associated with worse survival (hazard ratio, 1.43; 95% confidence interval, 1.11-1.84) after adjusting for age, sex, race, ethnicity, Child Pugh class, alpha-fetoprotein, Barcelona Clinic Liver Cancer stage, and HCC treatment. CONCLUSIONS: Nearly 1 in 4 patients with HCC present with cachexia, including many with compensated cirrhosis or early stage tumors. The presence of cancer-associated weight loss appears to be an early and independent predictor of worse outcomes in patients with HCC.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Rich NE, Phen S, Desai N, et al. Cachexia is Prevalent in Patients With Hepatocellular Carcinoma and Associated With Worse Prognosis. Clin Gastroenterol Hepatol. 2021. PMID: 34555519. doi:10.1016/j.cgh.2021.09.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。